March 20th 2024
Older adults with advanced breast cancer need personalized treatment plans considering fitness, preferences, and potential limitations for optimal outcomes and quality of life.
Novel Subcutaneous, At-Home Breast Cancer Treatment Approved
June 30th 2020The FDA approved Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) as a subcutaneous (SC) treatment for adult patients with metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer or early-stage HER-2 positive disease. The treatment combines 2 monoclonal antibodies in a single SC injection.
Read More
Previous Breast Cancer Therapy Not Likely to Affect Outcomes in Patients With COVID-19
June 26th 2020Results from an analysis of patients with breast cancer and coronavirus disease 2019 (COVID-19), from Institut Curie hospitals in France, show that mortality is determined more by comorbidities than previous or current treatment for the cancer.
Read More
Black Women With Insulin Resistance May Have Worse Breast Cancer Prognosis
June 24th 2020Elevated insulin levels, which have been shown to promote tumor growth, due to insulin resistance may be linked to a greater prevalence of invasive breast cancer among black women compared with white women.
Read More
High-Dose Chemo Most Benefits Patients With High-Risk Breast Cancer
June 11th 2020A 20-year follow-up comprising a secondary analysis to an original study shows that high-dose chemotherapy plus hematopoietic stem cell transplant benefit patients with high-risk stage III disease with 10 or more axillary lymph nodes involved.
Read More
Postmenopausal Women With Breast Cancer Show Decreased Brain Health, Cognitive Function
June 8th 2020Previous studies show that up to 75% of women with breast cancer exhibit disease- and treatment-related affects that include poorer cognitive function in the forms of psychological well-being, decision making, and adherence to treatment.
Read More
Long-Term Risk of Invasive Breast Cancer Increases Following a Diagnosis of DCIS
May 28th 2020In the 2 decades following their diagnosis for ductal carcinoma in situ (DCIS), women in a study out of England demonstrated a greater risk of invasive breast cancer and mortality compared with the general population. Overall, DCIS represents close to 20% of screening-detected breast cancers every year.
Read More
Women Frequently Encounter Employment, Insurance Issues After Breast Cancer Diagnosis
May 24th 2020A majority of women younger than 45 years faced employment and insurance coverage difficulties following treatment for early stage breast cancer, with 35% fearing loss of health insurance coverage if they left their current job during treatment—despite wanting to continue working.
Read More
Patients With Breast Cancer, COVID-19 Fared Well in Recent Study
May 20th 2020A small trial out of Columbia University Irving Medical Center shows encouraging recovery results among patients with breast cancer who contracted coronavirus disease 2019 (COVID-19), which was confirmed by reverse transcription-polymerase chain reaction, and/or high clinical or radiographic suspicion. Hospitalization was not necessary for nearly three-quarters of the patients.
Read More
Advanced, Fatal Breast Cancers Reduced Through Mammography Screening
May 11th 2020Fatal breast cancers were reduced by 41% and advanced breast cancers by 25% following recommended screening for the disease by mammography in 9 counties in Sweden, emphasizing the importance of early detection.
Read More
Study Attempts to Define Gains From Chemo for HR-Positive, HER2-Positive Breast Cancer
May 9th 2020Compared with tumors smaller than 8 mm among patients with hormone receptor (HR)-positive, ERBB2-positive (formerly HER2-positive) breast cancer, tumors between 8 and 10 mm benefited more from postoperative chemotherapy.
Read More
Consensus Called for When Choosing Optimal Treatment for Breast Cancer–Related Lymphedema
May 7th 2020More than 20% of breast cancer survivors are severely affected by breast cancer–related lymphedema, with debilitating adverse effects that include depression, chronic pain, and recurrent skin infections—all affecting overall quality of life.
Read More
In new data from the phase 3 EMBRACA trial presented yesterday at the American Association for Cancer Research annual meeting, researchers found that PARP inhibitor talazoparib exhibited no statistically significant benefit in the secondary end point of overall survival in patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Read More
Does Posttreatment Weight Loss Equate to Improved Quality of Life Among Survivors of Breast Cancer?
April 27th 2020An international team of investigators recently tried to answer this question, focusing on women with diagnosed early-stage disease and considered obese, with a body mass index above 30 kg/m2.
Read More
FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer
April 22nd 2020The FDA granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) as the first antibody-drug conjugate that targets the Trop-2 antigen. Trodelvy is indicated for treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC) that has spread to other parts of the body.
Read More